FDA Reform Bill Gives Commissioner Fixed Term, Adds Review Board
Executive Summary
The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act would mandate a fixed six-year term for the FDA commissioner, according to a draft of the bill obtained by “The Pink Sheet.” FDA’s centers would receive a chief medical policy officer.
You may also be interested in...
FDA, CDC Leaders Under Trump Urge Fixed Terms For US Health Agency Heads
Former FDA Commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.
Hahn Urges Fixed Terms For US FDA Leaders
Former commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.
FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit
Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.